Myasthenia Gravis Treatment Global Market By Drug Class, By Distribution Channel, By Treatment Type, By End User, By Regional Forecast 2024-2033 | Pfizer Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC,

Myasthenia Gravis Treatment Global Market

The Myasthenia Gravis Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Myasthenia Gravis Treatment Market:
https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report

According to The Business Research Company’s Myasthenia Gravis Treatment Global Market Report 2024, The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.42 billion in 2023 to $1.54 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%.  The growth in the historic period can be attributed to cholinesterase inhibitors, thymectomy procedures, immunosuppressive therapies, emergence of plasma exchange, patient advocacy.

The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.05 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%.  The growth in the forecast period can be attributed to biologics and monoclonal antibodies, genetic and precision medicine, emerging immune modulators, neuroprotective strategies, biosimilar medications. Major trends in the forecast period include digital therapeutics, collaborative research initiatives, patient-centric approaches, real-world evidence utilization, long-term safety monitoring.

The surge in the prevalence of myasthenia gravis is expected to propel the growth of the myasthenia gravis treatment market going forward. Myasthenia gravis refers to an autoimmune neuromuscular disease condition in which patients experience fatigue and weakness in the skeletal muscles. Myasthenia gravis treatment is the process of providing health care services and taking care of a patient to combat myasthenia gravis. Thus, the surge in the prevalence of myasthenia gravis is boosting sales in the myasthenia gravis treatment market. For instance, in January 2022, according to the data published by the National Organization for Rare Disorders, a US-based non-profit organization providing support for individuals with rare diseases, autoimmune myasthenia gravis had an estimated prevalence of 14–40 per 100,000 individuals in the United States. For instance, in December 2021, according to the study conducted by the Iran-based Kermanshah University of Medical Sciences and University Putra Malaysia, the global prevalence of myasthenia gravis was estimated to be 12.4 people per 100,000 people. Therefore, the surge in the prevalence of myasthenia gravis is driving the growth of the myasthenia gravis treatment market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp

The myasthenia gravis treatment market covered in this report is segmented –
1) By Treatment: Medication, Surgery, Other Treatments
2) By Medication Type: Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types
3) By End-Use: Hospitals, Clinics, Other End-Uses

Product innovations are a key trend gaining popularity in the myasthenia gravis treatment market. Major companies operating in the myasthenia gravis treatment market are focused on developing new solutions to sustain their position in the market. For example, in December 2021, Argenx SE, a Netherlands-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for its innovative drug VYVGARTô (efgartigimod alfa-fcab) for the treatment of anti-acetylcholine receptor (AChR) antibody-positive adult patients with generalized myasthenia gravis. With this approval, VYVGART has become the first and only FDA-approved neonatal Fc receptor (FcRn) blocker used for generalized myasthenia gravis treatment. The company has reached agreements in principle with several regional and national commercial payers to structure a value-based agreement, providing appropriate access for patients and predictability of cost for payers.

The myasthenia gravis treatment market report table of contents includes:
1. Executive Summary

  1. Myasthenia Gravis Treatment Market Characteristics
  2. Myasthenia Gravis Treatment Market Trends And Strategies
  3. Myasthenia Gravis Treatment Market – Macro Economic Scenario
  4. Global Myasthenia Gravis Treatment Market Size and Growth

…..

  1. Global Myasthenia Gravis Treatment Market Competitive Benchmarking
  2. Global Myasthenia Gravis Treatment Market Competitive Dashboard
  3. Key Mergers And Acquisitions In The Myasthenia Gravis Treatment Market
  4. Myasthenia Gravis Treatment Market Future Outlook and Potential Analysis
  5. Appendix

Related Reports
https://topprnews.com/print-label-market

https://topprnews.com/primary-school-market-size

https://topprnews.com/pressure-transducer-market

https://goodprnews.com/print-label-market

https://goodprnews.com/primary-school-market-size

https://goodprnews.com/pressure-transducer-market

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model